Phase 2 Study of FG-4592 in Subjects With Anemia and Chronic Kidney Disease Not Requiring Dialysis
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the safety, tolerability and
pharmacodynamic effects of 5 different oral doses of FG-4592 administered two times or three
times weekly for up to 4 weeks to subjects with Chronic Kidney Disease not requiring
dialysis.